Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Investments: 2017-2024

Historic Long-Term Investments for Syndax Pharmaceuticals (SNDX) over the last 4 years, with Dec 2024 value amounting to $119.5 million.

  • Syndax Pharmaceuticals' Long-Term Investments rose 100.88% to $20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 100.88%. This contributed to the annual value of $119.5 million for FY2024, which is 300.68% up from last year.
  • As of FY2024, Syndax Pharmaceuticals' Long-Term Investments stood at $119.5 million, which was up 300.68% from $29.8 million recorded in FY2023.
  • Syndax Pharmaceuticals' 5-year Long-Term Investments high stood at $119.5 million for FY2024, and its period low was $5.5 million during FY2022.
  • Its 3-year average for Long-Term Investments is $51.6 million, with a median of $29.8 million in 2023.
  • Data for Syndax Pharmaceuticals' Long-Term Investments shows a peak YoY skyrocketed of 445.42% (in 2023) over the last 5 years.
  • Syndax Pharmaceuticals' Long-Term Investments (Yearly) stood at $5.5 million in 2022, then spiked by 445.42% to $29.8 million in 2023, then skyrocketed by 300.68% to $119.5 million in 2024.